acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.
Company profile
Ticker
ABOS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ABOS stock data
Latest filings (excl ownership)
S-3
Shelf registration
27 Mar 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Results of Operations and Financial Condition
26 Mar 24
8-K
Corporate Presentation March 2024 1
19 Mar 24
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Corporate Presentation January 2024 1
12 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Corporate Presentation December 2023 1
4 Dec 23
8-K
Corporate Presentation November 2023 1
13 Nov 23
Transcripts
ABOS
Earnings call transcript
2023 Q4
26 Mar 24
ABOS
Earnings call transcript
2023 Q3
13 Nov 23
ABOS
Earnings call transcript
2023 Q2
8 Aug 23
ABOS
Earnings call transcript
2023 Q1
9 May 23
ABOS
Earnings call transcript
2022 Q4
27 Mar 23
ABOS
Earnings call transcript
2022 Q3
15 Nov 22
ABOS
Earnings call transcript
2022 Q2
16 Aug 22
ABOS
Earnings call transcript
2022 Q1
17 May 22
ABOS
Earnings call transcript
2021 Q4
28 Mar 22
Latest ownership filings
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
FRANKLIN RESOURCES INC
6 Feb 24
4
James J. Doherty
1 Feb 24
3
James J. Doherty
1 Feb 24
SC 13G/A
MURRAY JAMES B JR
24 Jan 24
4
Daniel Joseph OConnell
19 Jan 24
4
Derek M Meisner
19 Jan 24
4
Matt Zuga
19 Jan 24
4
Eric Siemers
19 Jan 24
4
Russell Barton
19 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 95.11 mm | 95.11 mm | 95.11 mm | 95.11 mm | 95.11 mm | 95.11 mm |
Cash burn (monthly) | (no burn) | 5.20 mm | 5.35 mm | 4.74 mm | 4.30 mm | 3.83 mm |
Cash used (since last report) | n/a | 31.15 mm | 32.01 mm | 28.39 mm | 25.75 mm | 22.93 mm |
Cash remaining | n/a | 63.96 mm | 63.10 mm | 66.72 mm | 69.35 mm | 72.18 mm |
Runway (months of cash) | n/a | 12.3 | 11.8 | 14.1 | 16.1 | 18.8 |
Institutional ownership, Q2 2023
49.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 53 |
Opened positions | 9 |
Closed positions | 16 |
Increased positions | 13 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 118.25 bn |
Total shares | 28.35 mm |
Total puts | 107.00 k |
Total calls | 341.90 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 9.77 mm | $47.00 bn |
Deep Track Capital | 3.92 mm | $18.84 bn |
Sands Capital Ventures | 3.42 mm | $16.44 bn |
Paul B Manning | 2.55 mm | $0.00 |
Laurion Capital Management | 1.21 mm | $5.80 bn |
Sands Capital Ventures Discovery Fund III | 1.15 mm | $23.15 mm |
Millennium Management | 1.15 mm | $5.51 bn |
Great Point Partners | 1.05 mm | $5.06 bn |
Vanguard | 734.85 k | $3.53 bn |
Ikarian Capital | 654.95 k | $3.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | James J. Doherty | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.11 | 601,000 | 1.87 mm | 601,000 |
19 Jan 24 | Derek M Meisner | Common Stock | Sell | Dispose S | No | Yes | 3.4757 | 8,933 | 31.05 k | 108,867 |
19 Jan 24 | Daniel Joseph OConnell | Common Stock | Sell | Dispose S | No | Yes | 3.4706 | 15,200 | 52.75 k | 502,485 |
18 Jan 24 | Russell Barton | Common Stock | Sell | Dispose S | No | Yes | 3.7258 | 2,833 | 10.56 k | 96,867 |
News
HC Wainwright & Co. Maintains Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
27 Mar 24
Acumen Pharmaceuticals Q4 EPS $(0.29) Misses $(0.26) Estimate
26 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Acumen Pharmaceuticals's Earnings: A Preview
25 Mar 24
Acumen Pharmaceuticals To Present Deeper Insights, Including Fluid Biomarker Data For Sabirnetug, During Emerging Science Session At The American Academy Of Neurology Annual Meeting
21 Mar 24
Press releases
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
12 Mar 24
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
8 Mar 24
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
21 Feb 24
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
1 Feb 24
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4 Jan 24